Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) is described in its own communications as a leader in life science research and clinical diagnostics products. Based in Hercules, California, the company operates globally and regularly issues news on its financial performance, technology platforms, and corporate developments. This news page aggregates recent BIO stock headlines and company announcements.
Investors and analysts following Bio-Rad can find updates on quarterly financial results, including segment performance for the Life Science and Clinical Diagnostics groups and commentary on factors such as academic research funding, biotech funding conditions, and reimbursement trends in key markets. The company frequently discusses both GAAP and non-GAAP results, along with explanations of how non-GAAP measures are used in its internal analysis.
Bio-Rad’s news flow also covers product and technology updates, particularly around its Droplet Digital PCR (ddPCR) portfolio. Recent releases describe the launch of new ddPCR platforms, the integration of technologies from the acquisition of Stilla Technologies, and webinars or presentations focused on its ddPCR product line. These items provide insight into how the company is expanding its presence in genomics research and applied science applications.
Additional news items include announcements about participation in healthcare and investor conferences, leadership appointments, and historical and corporate milestones. For example, the company has reported on executive leadership changes and has issued statements regarding the passing of its co-founder and Director Emeritus, Alice N. Schwartz. Users interested in BIO news can use this page to review these updates in one place and to track how Bio-Rad communicates its strategy and operations over time.
Bio-Rad Laboratories reported Q4 2020 results with net sales of $789.8 million, a 26.5% increase from Q4 2019. Life Science segment sales surged 77.1% to $428.5 million, largely driven by COVID-19-related demand. Gross margin improved to 58.3% from 52.9% year-over-year. Net income soared to $839.1 million, or $27.81 per share, compared to $553.5 million, or $18.31 per share in Q4 2019. Clinical Diagnostics segment saw a 5.1% decrease in sales. The company was awarded Emergency Use Authorization for new COVID-19 tests.
Bio-Rad Laboratories will announce its financial results for Q4 and full year 2020 on February 11, 2021, post-market. A conference call to discuss these results is scheduled for 3 PM PT (6 PM ET) the same day. Investors can access the call by dialing 855-779-9068 within the U.S. or 631-485-4862 internationally, using Conference ID: 8269933. The call will also be available via a webcast on the company’s Investor Relations page, which will remain accessible for one year.
Bio-Rad Laboratories (NYSE: BIO, BIOb) announced participation in a virtual Fireside Chat at the 39th Annual J.P. Morgan Healthcare Conference on January 11 at 1:30 PM PST. The event will feature President and CEO Norman Schwartz, COO Andrew Last, and CFO Ilan Daskal. Investors can access the live webcast through the Investor Relations section on bio-rad.com. Founded in 1952, Bio-Rad is a leader in life science research and clinical diagnostics, with over $2.3 billion in revenue in 2019 and a workforce of more than 8,000 employees globally.
Bio-Rad Laboratories (NYSE: BIO) has announced its 2023 outlook, projecting sales between $2.75 billion and $2.85 billion. The forecast reflects the company's strong product portfolio, including Droplet Digital PCR and clinical diagnostics. Bio-Rad expects a non-GAAP adjusted EBITDA margin of 23-24%, aided by operating leverage and improvements in capacity utilization. CEO Norman Schwartz emphasized a focus on balancing innovation with operational discipline to support organic growth and sustainability efforts.
Bio-Rad Laboratories, Inc. (NYSE: BIO) will announce its third-quarter 2020 financial results on October 29, 2020, after the market closes. A conference call is scheduled for 3 PM PT (6 PM ET) to discuss these results. The call can be accessed by dialing 855-779-9068 for U.S. callers or 631-485-4862 for international callers, using passcode 7061137. Additionally, interested parties can listen to the live webcast on the Investor Relations section of the company's website.